SAB Biotherapeutics (NASDAQ:SABS – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports. According to Zacks, “SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, […]
SAB Biotherapeutics (NASDAQ:SABS – Get Rating) and BioCardia (NASDAQ:BCDA – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership. Analyst Ratings This is a summary of current ratings and […]
SAB Biotherapeutics (NASDAQ:SABS – Get Rating) had its price target trimmed by Chardan Capital from $17.00 to $10.00 in a research report sent to investors on Friday, The Fly reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also issued reports on SABS. Northland Securities raised their target price […]